Arehelli S Manjappa

Dr. Arehelli S Manjappa

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2023 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
SDSunil T. Dhere
Sunil T. Dhere
AMArehelli S Manjappa
Arehelli S Manjappa
Durgacharan Arun BhagwatDurgacharan Arun Bhagwat
Durgacharan Arun Bhagwat
RTRahul Trivedi
Rahul Trivedi
Ahmad SalawiAhmad Salawi
Ahmad Salawi
AAAbdullah Alsalhi
Abdullah Alsalhi
1

1 September 2020 in Annales Pharmaceutiques Françaises
Verified
Journal Article
Closed access
PKP.S. Kumbhar
P.S. Kumbhar
SDSonali K. Diwate
Sonali K. Diwate
UMU.G. Mali
U.G. Mali
TST.U. Shinde
T.U. Shinde
JDJ.I. Disouza
J.I. Disouza
AMArehelli S Manjappa
Arehelli S Manjappa

16 December 2019 in Future Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
AMArehelli S Manjappa
Arehelli S Manjappa
PKPopat S. Kumbhar
Popat S. Kumbhar
RKRohini Kasabe
Rohini Kasabe
SDSonali K. Diwate
Sonali K. Diwate
JDJohn I. Disouza
John I. Disouza
Background: Methotrexate (MTX), a folate anti-metabolite, has been used widely in the treatment of plenty of malignancies. However, the clinical use is limited because of its poor water solubility (BCS class II drug), nonspecific distribution, drug resistance, short circulation half-life, and toxicity. The objective of the present research was to synthesize the ester prodrug of MTX with d-α-Tocopheryl polyethylene glycol 1000 succinate (TPGS) and characterize for in vitro anticancer efficacy. Results: The FTIR and NMR results revealed the successful synthesis of the prodrug. The assay and saturation solubility of the prodrug is found to be 23 ± 2.5% and 6.7 ± 1.3 mg/mL (MTX equivalent) respectively. The CMC of the prodrug in distilled water at room temperature is found to be 36.9 ± 2.6 μg/mL. The prepared prodrug micelles showed a mean particle size of 166 ± 10 nm (PDI, 0.325 ± 0.09). Further, the TEM results confirmed the self-assembling character of the prodrug into micelles with a nearly spherical shape. The prodrug caused the significantly (p < 0.01) less hemolysis (16.8 ± 1.5%) when compared to plain MTX solution and significantly higher (p < 0.01) in vitro cytotoxicity, cell cycle arresting, and apoptosis against human breast cancer cells (MCF-7 and MDA-MB-231). Conclusion: Our study results revealed the remarkable in vitro anticancer activity of MTX following its esterification with TPGS. However, further, in vivo studies are needed to prove its efficacy against different cancers.

15 December 2022 in Annales Pharmaceutiques Françaises
Verified
Journal Article
Closed access
SDSunil T. Dhere
Sunil T. Dhere
AMArehelli S Manjappa
Arehelli S Manjappa
PKP.S. Kumbhar
P.S. Kumbhar
ASA. Salawi
A. Salawi
FSFahad Y. Sabei
Fahad Y. Sabei
MKM.N. Kagale
M.N. Kagale

3 November 2018 in Colloid and Polymer Science
Verified
Journal Article
Closed access
PDF file
PKPopat S. Kumbhar
Popat S. Kumbhar
SBSwapnil Birange
Swapnil Birange
MAMahesh Atavale
Mahesh Atavale
JDJohn I. Disouza
John I. Disouza
AMArehelli S Manjappa
Arehelli S Manjappa

16 May 2025 in Indian Journal of Pharmaceutical Education and Research
Verified
Journal Article
Open access
PDF file
SHSwapnil Harale
Swapnil Harale
AKAviraj Kadam
Aviraj Kadam
SDSunil T. Dhere
Sunil T. Dhere
AMArehelli S Manjappa
Arehelli S Manjappa
RKRushikesh Katkar
Rushikesh Katkar
GKGourisankar Kandukuri
Gourisankar Kandukuri
Background: Breast cancer is the leading and most frequent cancer among women worldwide, with rapidly growing new cases diagnosed, surpassing lung cancer. The current study aims to design, optimize and characterize Letrozole (LTZ) Loaded Ethosomes (LTZ-ETH) for the treatment of breast cancer. Materials and Methods: Ethosomes were optimized using a two-factor, three-level (32) factorial design technique. The ethosomes were characterized by vesicle size, zeta potential and entrapment efficiency. The optimized LTZ-ETH was tested for surface morphology and in vitro cytotoxicity. Results: The optimized LTZ-ETH has flawed round-shaped unilamellar structures with an average vesicle size of 218.6 ± 5 nm and an entrapment efficiency of 92.45±3.42%. Optimized LTZ-ETH demonstrated significant (p<0.01) in vitro cytotoxicity (IC50: 23.27±1.48 μg/mL) than LTZ (58.70±2.46 μg/mL) against MCF-7 Cells. Compared to LTZ, LTZ-ETH treatment caused apoptosis of large proportion of cancer cells. The above results could be correlated to the increased cell uptake of LTZ-ETH as shown by in vitro cell uptake study. Furthermore, the in vitro skin permeation study results revealed enhanced penetration of LTZ-ETH into the deeper layers of the skin. Conclusion: The study results revealed that LTZ-ETH could be used as a potential alternative treatment approach to conventional chemotherapy. However; further in vivo animal studies are required to establish its efficacy in the treatment of breast cancer.